ClinicalTrials.Veeva

Menu

Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials

I

Istanbul Bakirkoy Maternity and Children Diseases Hospital

Status and phase

Completed
Phase 4

Conditions

Pelvic Inflammatory Disease

Treatments

Drug: Moxifloxacin
Drug: Ofloxacin
Drug: Metronidazole

Study type

Interventional

Funder types

Other

Identifiers

NCT01799356
Asicioglu03
treatment uPID (Other Identifier)
treatment (Other Identifier)

Details and patient eligibility

About

We aimed to compare efficacy and safety of combination therapy with oral ofloxacin, 400 mg twice daily, plus oral metronidazole, 500 mg twice daily, for 14 days, with moxifloxacin monotherapy, 400 mg once daily, for 14 days

Enrollment

1,303 patients

Sex

Female

Ages

14 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Women diagnosed uncomplicated PID
  2. Patients age are between 14 with 45
  3. Pelvic tenderness and vaginal discharge

Exclusion criteria

  1. Urinary Tract Enfections
  2. Tubo-ovarian abscess and complicated PID
  3. Hıstory of antibiotics treatment
  4. Other pelvic pain causes
  5. Endometriosis
  6. Delivery,abortion and surgery within last months

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

1,303 participants in 2 patient groups, including a placebo group

moxifloxacin Group
Active Comparator group
Description:
Treatment at uPID with moxifloxacin
Treatment:
Drug: Moxifloxacin
Ofloxacin Group
Placebo Comparator group
Description:
Treatment at uPID with Ofloxacin plus metronidazole
Treatment:
Drug: Metronidazole
Drug: Ofloxacin

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems